Vanguard Group
IKT icon

Vanguard Group’s Inhibikase Therapeutics IKT Stock Holding History

Vanguard Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.35M Buy
4,558,604
+1,285,265
+39% +$2.05M ﹤0.01% 2993
2025
Q3 		$5.3M Buy
3,273,339
+48,969
+2% +$84.8K ﹤0.01% 3260
2025
Q2 		$6.29M Buy
3,224,370
+375,707
+13% +$736K ﹤0.01% 3130
2025
Q1 		$6.24M Buy
2,848,663
+10,018
+0.4% +$25.2K ﹤0.01% 3085
2024
Q4 		$9.23M Buy
2,838,645
+2,821,921
+16,873% +$7.04M ﹤0.01% 3001
2024
Q3 		$21.7K Hold
16,724
– – ﹤0.01% 4298
2024
Q2 		$20.2K Hold
16,724
– – ﹤0.01% 4359
2024
Q1 		$36.1K Sell
16,724
-65,321
-80% -$144K ﹤0.01% 4347
2023
Q4 		$104K Sell
82,045
-5,402
-6% -$5.59K ﹤0.01% 4294
2023
Q3 		$122K Sell
87,447
-863
-1% -$1.93K ﹤0.01% 4322
2023
Q2 		$319K Sell
88,310
-69
-0.1% -$257 ﹤0.01% 4225
2023
Q1 		$349K Hold
88,379
– – ﹤0.01% 4215
2022
Q4 		$265K Buy
88,379
+29
+0% +$115 ﹤0.01% 4248
2022
Q3 		$482K Hold
88,350
– – ﹤0.01% 4223
2022
Q2 		$394K Hold
88,350
– – ﹤0.01% 4344
2022
Q1 		$785K Buy
88,350
+8,566
+11% +$68.9K ﹤0.01% 4283
2021
Q4 		$704K Hold
79,784
– – ﹤0.01% 4360
2021
Q3 		$909K Buy
79,784
+1,348
+2% +$18.2K ﹤0.01% 4266
2021
Q2 		$1.32M Buy
+78,436
New +$2.31M ﹤0.01% 4094

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM

Vanguard Group's IKT Position: Q4 2025 in Review

Vanguard Group increased its Inhibikase Therapeutics (IKT) stake by 39% in Q4 2025, buying an estimated $2.05M and bringing the position to 4,558,604 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

Vanguard Group first reported a position in IKT in Q2 2021 and has held it in 19 quarters since. 74 funds tracked by Wall St. Rank hold IKT as of Q4 2025.

  • Vanguard Group held 4,558,604 shares of Inhibikase Therapeutics worth $9.35M as of Q4 2025.
  • Vanguard Group bought 1,285,265 Inhibikase Therapeutics shares in Q4 2025, an estimated $2.05M.
  • Inhibikase Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2993 holding.
  • Vanguard Group first reported a position in Inhibikase Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 74 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.